Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125661851 | 12566185 | 1 | I | 201606 | 20160714 | 20160718 | 20160718 | EXP | US-GLAXOSMITHKLINE-US2016101340 | GLAXOSMITHKLINE | 74.89 | YR | M | Y | 0.00000 | 20160718 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125661851 | 12566185 | 1 | PS | ADVAIR DISKUS | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | 1 PUFF(S), PRN | U | 21077 | 1 | DF | INHALATION POWDER | |||||||
125661851 | 12566185 | 2 | SS | VENTOLIN HFA | ALBUTEROL SULFATE | 1 | 1 PUFF(S), PRN | U | 0 | 1 | DF |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125661851 | 12566185 | 1 | Lung disorder |
125661851 | 12566185 | 2 | Lung disorder |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125661851 | 12566185 | OT |
125661851 | 12566185 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125661851 | 12566185 | Cardiac failure congestive | |
125661851 | 12566185 | Dyspnoea | |
125661851 | 12566185 | Intentional product use issue | |
125661851 | 12566185 | Myocardial infarction |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125661851 | 12566185 | 1 | 2014 | 0 | ||
125661851 | 12566185 | 2 | 2014 | 0 |